top of page
DEMETHER
A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL EXPLORING THE MAINTENANCE OF TRASTUZUMAB AND PERTUZUMAB FOLLOWING TRASTUZUMAB DERUXTECAN AS INDUCTION TREATMENT FOR HER2-POSITIVE UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (mBC) PATIENTS
CLINICAL TRIAL DETAILS
A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL EXPLORING THE MAINTENANCE OF TRASTUZUMAB AND PERTUZUMAB FOLLOWING TRASTUZUMAB DERUXTECAN AS INDUCTION TREATMENT FOR HER2-POSITIVE UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER PATIENTS (DEMETHER).
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Breast Cancer
165
II
EU
Recruitment
PRESS RELEASE
----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
----
TRIAL SITES
----
bottom of page